. 2018 Jun 8;1(2):133–140. doi: 10.1002/agm2.12023

Table 3.

Univariate analysis of prognostic factors and overall pain response

Variable	Odds ratio	95% confidence interval	Wald statistic	P‐value
Age
< 65	1.000	‐	‐	‐
≥65	1.193	0.605‐2.353	0.258	.611
Gender
Male	1.000	‐	‐	‐
Female	1.823	0.942‐3.527	3.178	.075^a
ECOG
< 2	3.240	1.689‐6.213	12.526	<.001^a
≥2	1.000	‐	‐	‐
Primary tumor
Breast	5.000	1.959‐12.762	11.333	.001^a
Lung	2.344	0.795‐6.908	2.385	.122^a
Prostate	4.286	1.238‐14.831	5.279	.022^a
Others	1.000	‐	‐	‐
Extent of bone metastases
Single	1.000	‐	‐	‐
Multiple	1.027	0.265‐3.973	0.001	.969
Treatment site
Spine	1.067	0.269‐4.235	0.008	.927
Pelvis	1.033	0.250‐4.269	0.002	.964
Extremities	0.600	0.082‐4.400	0.253	.615
Others	1.000	‐	‐	‐
Fractionation
Single	1.000	‐	‐	‐
Multiple	1.299	0.690‐2.446	0.658	.417
Bone‐targeting agent
Yes	1.693	0.898‐3.192	2.650	.104^a
No	1.000	‐	‐	‐
Systemic treatment
Yes	1.256	0.573‐2.752	0.323	.570
No	1.000	‐	‐	‐

The variables selected (P < .25) for the preliminary main‐effect model are gender, ECOG, primary tumor, and bone‐targeting agent.